Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › pegylated interferon alfa-2a

pegylated interferon alfa-2a

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of pegylated interferon alfa-2a

23 trials tracked of pegylated interferon alfa-2a: 10 in phase 3 or 4 and 1 with published results. The most-cited published study has 10 citations.

23Trials tracked
10Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 10 Phase 2 11 Other / NA 2
  1. Phase 3 The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE) Completed · 10 cited
  2. Phase 3 A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies Completed
  3. Phase 3 A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase Completed
  4. Phase 3 Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C] Completed
  5. Phase 3 Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C Completed
  6. Phase 3 Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C Completed
Show 17 more trials
  1. Phase 3 Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV) Completed
  2. Phase 3 VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection Completed
  3. Phase 3 A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV) Completed
  4. Phase 3 A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols Completed
  5. Phase 2 Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection Completed
  6. Phase 2 Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials Completed
  7. Phase 2 Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection Completed
  8. Phase 2 Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects Completed
  9. Phase 2 An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection Completed
  10. Phase 2 Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C Completed
  11. Phase 2 Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2) Completed
  12. Phase 2 Directly Observed Therapy for HCV in Chennai, India Completed
  13. Phase 2 A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3) Completed
  14. Phase 2 Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C Completed
  15. Phase 2 A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy Completed
  16. N/A Observational Study Evaluating the Quality of Pegylated Interferon Alfa-2a and Ribavirin Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists) Completed
  17. N/A A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C Completed

Showing the 23 most-cited and recently-updated of 23 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Combining pegylated interferon with nilotinib improves early molecular response in newly diagnosed chronic phase chronic myeloid leukaemia
Oncology RCT
Combining pegylated interferon with nilotinib improves early molecular response in newly diagnosed chronic phase chronic myeloid leukaemia Adding a weekly shot to a daily leukemia pill boosts deep remission rates
This phase 3 trial compared nilotinib monotherapy against nilotinib combined with pegylated interferon alfa-2a in patients with newly diagno…
A weekly injection added to a daily pill helped more newly diagnosed CML patients reach deep remission, but it also caused more side effects…
May 3, 2026